ArticleScientific reports2025
Formulation and evaluation of taste-masked curcumin nanoparticles for improved antioxidant and anticancer efficacy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Curcumin, a natural polyphenolic compound derived from turmeric, is well-documented for its therapeutic properties, including anti-inflammatory, antioxidant, antimicrobial, and anticancer activities. However, its clinical and nutraceutical applications are limited by its poor aqueous solubility, low oral bioavailability, and unpleasant taste. This study aimed to encapsulate curcumin in alginate-based nanoparticles, with and without chitosan coating, to improve its palatability while preserving its therapeutic efficacy. Two optimized formulations uncoated curcumin-loaded alginate nanoparticles (CANPs) and chitosan-coated nanoparticles (CANPs-Cs) were developed, exhibiting average particle sizes of 199.51 ± 9.40 nm and 312.90 ± 10.30 nm, polydispersity indices of 0.26 ± 0.090 and 0.27 ± 0.09, zeta potentials of - 23.10 ± 1.10 mV and + 28.50 ± 1.00 mV, encapsulation efficiencies of 93.6 ± 3.5% and 90.8 ± 0.1%, and drug loading of 1.32 ± 0.15% and 1.25 ± 0.19%, respectively. FTIR analysis confirmed the compatibility and successful encapsulation of curcumin within the nanoparticle matrix. The chitosan-coated formulation (CANPs-Cs) exhibited enhanced antioxidant activity and superior taste-masking ability, as evidenced by a significant reduction (~ 50%) in curcumin release within artificial saliva compared to CANPs. Additionally, both formulations demonstrated potent cytotoxic effects against the CT26 colon cancer cell line, with CANPs-Cs maintaining therapeutic efficacy while offering improved sensory attributes. These findings suggest that CANPs-Cs is a promising delivery system for curcumin, offering enhanced bioactivity and palatability suitable for food and pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.